[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiQczMCpkWgA5TogyzkLEu7w2IE9cL9wRmBZd45gTJJs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Baylor Research Institute",[4],220,false,65,4,64111,56,153,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Spinal Cord Injuries",8,{"name":18,"count":19},"Stroke",7,{"name":21,"count":22},"Heart Failure",6,{"name":24,"count":25},"Breast Cancer",5,{"name":27,"count":9},"Atrial Fibrillation",{"name":29,"count":9},"Aortic Stenosis",{"name":31,"count":9},"Cardiovascular Diseases",{"name":33,"count":9},"Obesity",[35,40,45,50,55,60,63,67,72,77],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03480568","Alirocumab in Patients on a Stable Dialysis Regimen","2020-08-31","Alirocumab 150 MG\u002FML [Praluent]",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04921904","Abemaciclib Plus Ramucirumab for Esophageal\u002FGastroesophageal Junction Ca","2024-12-31","Abemaciclib",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04496362","Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study","2025-02-12","subcutaneous heparin anticoagulation",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06505148","Comparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?","2025-08-01","Acetaminophen",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04926467","Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)","2026-06","Anakinra",{"nctId":61,"briefTitle":62,"date":58,"intervention":54},"NCT06997016","Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients",{"nctId":64,"briefTitle":65,"date":58,"intervention":66},"NCT06008275","Neratinib in Combination With Ruxolitinib in Patients With mTNBC","Neratinib Oral",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06588348","Corticosteroid Effect on Achalasia Variant EGJOO","2026-11","Steroid treatment",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03383419","Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","2026-12-30","Epclusa",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04265872","Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","2026-12-31","Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro\u002Fcis",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,126,172,196,222,240,258,276,302,320,338,388,406,424,442,460,478,496,514,532,550,568,586,604,622,640,658,676,694,712,730,748,766,784,802,820,848,866,884,902,920,938,956,985,1011,1059,1086,1104,1126,1144,1171,1191,1211,1233,1251,1272,1299,1324,1351,1369,1396,1421,1452,1478,1496,1514,1532,1550,1579,1597,1626,1644,1672,1690,1708,1726,1752,1776,1801,1828,1846,1872,1897,1922,1946,1970,1997,2022,2050,2075,2101,2127,2151,2169,2194,2220,2243,2268,2293,2331,2355,2373,2391,2409,2433,2457,2481,2505,2539,2557,2575,2593,2611,2638,2656,2686,2704,2722,2740,2758,2783,2806],{"intervention":54,"totalTrials":91,"cells":92},2,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":124},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":53},[104,115],{"nctId":61,"briefTitle":62,"status":105,"phases":106,"primaryCompletion":58,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"ENROLLING_BY_INVITATION",[87],"2027-06","2025-05-05",60,[111],"Postoperative Pain",[54,113,114],"Gabapentin","Bupivacaine",{"nctId":51,"briefTitle":52,"status":116,"phases":117,"primaryCompletion":53,"completion":53,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NOT_YET_RECRUITING",[87],"2024-08-01",80,[121],"Pediatric Disorder",[54,123],"Ibuprofen",{"trials":125,"activeCount":95},[],{"intervention":127,"totalTrials":91,"cells":128},"Tacrolimus",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":170},{"trials":130,"activeCount":95},[],{"trials":132,"activeCount":95},[],{"trials":134,"activeCount":95},[],{"trials":136,"activeCount":95},[],{"trials":138,"activeCount":169,"soonestReadout":159},[139,155],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":151},"NCT00163657","Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection","COMPLETED",[87],"2006-04","2007-01","2002-07",312,[149,150],"End Stage Liver Disease","Hepatitis C",[152,127,153,154],"Daclizumub","Cyclosporine","MMF",{"nctId":156,"briefTitle":157,"status":105,"phases":158,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},"NCT02081755","Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer",[87],"2027-03","2014-03",336,[163],"Carcinoma, Hepatocellular",[165,127,166,167,168],"Everolimus","Myfortic","CellCept","Imuran",1,{"trials":171,"activeCount":95},[],{"intervention":49,"totalTrials":169,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":194},{"trials":175,"activeCount":95},[],{"trials":177,"activeCount":95},[],{"trials":179,"activeCount":95},[],{"trials":181,"activeCount":95},[],{"trials":183,"activeCount":169,"soonestReadout":48},[184],{"nctId":46,"briefTitle":47,"status":185,"phases":186,"primaryCompletion":48,"completion":58,"start":187,"enrollment":188,"conditions":189,"interventions":193},"ACTIVE_NOT_RECRUITING",[87],"2018-10-10",100,[190,191,192],"ECMO","Heparin","Respiratory Failure",[49],{"trials":195,"activeCount":95},[],{"intervention":197,"totalTrials":169,"cells":198},"Skin Substitute",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":220},{"trials":200,"activeCount":95},[],{"trials":202,"activeCount":95},[],{"trials":204,"activeCount":95},[],{"trials":206,"activeCount":95},[],{"trials":208,"activeCount":169,"soonestReadout":213},[209],{"nctId":210,"briefTitle":211,"status":116,"phases":212,"primaryCompletion":213,"completion":213,"start":58,"enrollment":214,"conditions":215,"interventions":219},"NCT07587749","Skin Subs vs Secondary Intention",[87],"2027-12",50,[216,217,218],"Skin Substitutes","Secondary Intention Healing","Skin Cancer Healing",[197,217],{"trials":221,"activeCount":95},[],{"intervention":217,"totalTrials":169,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":238},{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":95},[],{"trials":229,"activeCount":95},[],{"trials":231,"activeCount":95},[],{"trials":233,"activeCount":169,"soonestReadout":213},[234],{"nctId":210,"briefTitle":211,"status":116,"phases":235,"primaryCompletion":213,"completion":213,"start":58,"enrollment":214,"conditions":236,"interventions":237},[87],[216,217,218],[197,217],{"trials":239,"activeCount":95},[],{"intervention":113,"totalTrials":169,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":256},{"trials":243,"activeCount":95},[],{"trials":245,"activeCount":95},[],{"trials":247,"activeCount":95},[],{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":169,"soonestReadout":58},[252],{"nctId":61,"briefTitle":62,"status":105,"phases":253,"primaryCompletion":58,"completion":107,"start":108,"enrollment":109,"conditions":254,"interventions":255},[87],[111],[54,113,114],{"trials":257,"activeCount":95},[],{"intervention":114,"totalTrials":169,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":274},{"trials":261,"activeCount":95},[],{"trials":263,"activeCount":95},[],{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":169,"soonestReadout":58},[270],{"nctId":61,"briefTitle":62,"status":105,"phases":271,"primaryCompletion":58,"completion":107,"start":108,"enrollment":109,"conditions":272,"interventions":273},[87],[111],[54,113,114],{"trials":275,"activeCount":95},[],{"intervention":277,"totalTrials":169,"cells":278},"Norco 5Mg-325Mg",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":300},{"trials":280,"activeCount":95},[],{"trials":282,"activeCount":95},[],{"trials":284,"activeCount":95},[],{"trials":286,"activeCount":95},[],{"trials":288,"activeCount":169,"soonestReadout":213},[289],{"nctId":290,"briefTitle":291,"status":105,"phases":292,"primaryCompletion":213,"completion":213,"start":293,"enrollment":294,"conditions":295,"interventions":298},"NCT07575230","Suzetrigine vs Norco-postoperative Mohs Pain",[87],"2025-11-03",75,[296,297],"Cutaneous Tumors","Mohs Micrographic Surgery",[277,299],"Suzetrigine",{"trials":301,"activeCount":95},[],{"intervention":299,"totalTrials":169,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":305,"activeCount":95},[],{"trials":307,"activeCount":95},[],{"trials":309,"activeCount":95},[],{"trials":311,"activeCount":95},[],{"trials":313,"activeCount":169,"soonestReadout":213},[314],{"nctId":290,"briefTitle":291,"status":105,"phases":315,"primaryCompletion":213,"completion":213,"start":293,"enrollment":294,"conditions":316,"interventions":317},[87],[296,297],[277,299],{"trials":319,"activeCount":95},[],{"intervention":123,"totalTrials":169,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":336},{"trials":323,"activeCount":95},[],{"trials":325,"activeCount":95},[],{"trials":327,"activeCount":95},[],{"trials":329,"activeCount":95},[],{"trials":331,"activeCount":169,"soonestReadout":53},[332],{"nctId":51,"briefTitle":52,"status":116,"phases":333,"primaryCompletion":53,"completion":53,"start":118,"enrollment":119,"conditions":334,"interventions":335},[87],[121],[54,123],{"trials":337,"activeCount":95},[],{"intervention":339,"totalTrials":169,"cells":340},"Finerenone",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":386},{"trials":342,"activeCount":95},[],{"trials":344,"activeCount":95},[],{"trials":346,"activeCount":95},[],{"trials":348,"activeCount":95},[],{"trials":350,"activeCount":169,"soonestReadout":355},[351],{"nctId":352,"briefTitle":353,"status":116,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":361},"NCT07547878","Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)",[87],"2029-03-31","2026-04-30",64,[359,360],"Chronic Kidney Disease","Type 2 Diabetes",[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],"Semaglutide","Lotensin","Capoten","Enalapril","Monopril","Lisinopril","Univasc","Aceon","Accupril","Altace","Mavik","Edarbi","Atacand","Avapro","Cozaar","Benicar","Micardis","Diovan","Invokana","Farxiga","Jardiance","Ertugliflozin","Brenzavvy","Sotagliflozin",{"trials":387,"activeCount":95},[],{"intervention":362,"totalTrials":169,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":404},{"trials":391,"activeCount":95},[],{"trials":393,"activeCount":95},[],{"trials":395,"activeCount":95},[],{"trials":397,"activeCount":95},[],{"trials":399,"activeCount":169,"soonestReadout":355},[400],{"nctId":352,"briefTitle":353,"status":116,"phases":401,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":402,"interventions":403},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":405,"activeCount":95},[],{"intervention":363,"totalTrials":169,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":422},{"trials":409,"activeCount":95},[],{"trials":411,"activeCount":95},[],{"trials":413,"activeCount":95},[],{"trials":415,"activeCount":95},[],{"trials":417,"activeCount":169,"soonestReadout":355},[418],{"nctId":352,"briefTitle":353,"status":116,"phases":419,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":420,"interventions":421},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":423,"activeCount":95},[],{"intervention":364,"totalTrials":169,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":440},{"trials":427,"activeCount":95},[],{"trials":429,"activeCount":95},[],{"trials":431,"activeCount":95},[],{"trials":433,"activeCount":95},[],{"trials":435,"activeCount":169,"soonestReadout":355},[436],{"nctId":352,"briefTitle":353,"status":116,"phases":437,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":438,"interventions":439},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":441,"activeCount":95},[],{"intervention":365,"totalTrials":169,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":458},{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[],{"trials":451,"activeCount":95},[],{"trials":453,"activeCount":169,"soonestReadout":355},[454],{"nctId":352,"briefTitle":353,"status":116,"phases":455,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":456,"interventions":457},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":459,"activeCount":95},[],{"intervention":366,"totalTrials":169,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":476},{"trials":463,"activeCount":95},[],{"trials":465,"activeCount":95},[],{"trials":467,"activeCount":95},[],{"trials":469,"activeCount":95},[],{"trials":471,"activeCount":169,"soonestReadout":355},[472],{"nctId":352,"briefTitle":353,"status":116,"phases":473,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":474,"interventions":475},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":477,"activeCount":95},[],{"intervention":367,"totalTrials":169,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":95},[],{"trials":483,"activeCount":95},[],{"trials":485,"activeCount":95},[],{"trials":487,"activeCount":95},[],{"trials":489,"activeCount":169,"soonestReadout":355},[490],{"nctId":352,"briefTitle":353,"status":116,"phases":491,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":492,"interventions":493},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":495,"activeCount":95},[],{"intervention":368,"totalTrials":169,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":95},[],{"trials":505,"activeCount":95},[],{"trials":507,"activeCount":169,"soonestReadout":355},[508],{"nctId":352,"briefTitle":353,"status":116,"phases":509,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":510,"interventions":511},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":513,"activeCount":95},[],{"intervention":369,"totalTrials":169,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":530},{"trials":517,"activeCount":95},[],{"trials":519,"activeCount":95},[],{"trials":521,"activeCount":95},[],{"trials":523,"activeCount":95},[],{"trials":525,"activeCount":169,"soonestReadout":355},[526],{"nctId":352,"briefTitle":353,"status":116,"phases":527,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":528,"interventions":529},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":531,"activeCount":95},[],{"intervention":370,"totalTrials":169,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":548},{"trials":535,"activeCount":95},[],{"trials":537,"activeCount":95},[],{"trials":539,"activeCount":95},[],{"trials":541,"activeCount":95},[],{"trials":543,"activeCount":169,"soonestReadout":355},[544],{"nctId":352,"briefTitle":353,"status":116,"phases":545,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":546,"interventions":547},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":549,"activeCount":95},[],{"intervention":371,"totalTrials":169,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":566},{"trials":553,"activeCount":95},[],{"trials":555,"activeCount":95},[],{"trials":557,"activeCount":95},[],{"trials":559,"activeCount":95},[],{"trials":561,"activeCount":169,"soonestReadout":355},[562],{"nctId":352,"briefTitle":353,"status":116,"phases":563,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":564,"interventions":565},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":567,"activeCount":95},[],{"intervention":372,"totalTrials":169,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":584},{"trials":571,"activeCount":95},[],{"trials":573,"activeCount":95},[],{"trials":575,"activeCount":95},[],{"trials":577,"activeCount":95},[],{"trials":579,"activeCount":169,"soonestReadout":355},[580],{"nctId":352,"briefTitle":353,"status":116,"phases":581,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":582,"interventions":583},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":585,"activeCount":95},[],{"intervention":373,"totalTrials":169,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":602},{"trials":589,"activeCount":95},[],{"trials":591,"activeCount":95},[],{"trials":593,"activeCount":95},[],{"trials":595,"activeCount":95},[],{"trials":597,"activeCount":169,"soonestReadout":355},[598],{"nctId":352,"briefTitle":353,"status":116,"phases":599,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":600,"interventions":601},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":603,"activeCount":95},[],{"intervention":374,"totalTrials":169,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":620},{"trials":607,"activeCount":95},[],{"trials":609,"activeCount":95},[],{"trials":611,"activeCount":95},[],{"trials":613,"activeCount":95},[],{"trials":615,"activeCount":169,"soonestReadout":355},[616],{"nctId":352,"briefTitle":353,"status":116,"phases":617,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":618,"interventions":619},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":621,"activeCount":95},[],{"intervention":375,"totalTrials":169,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":638},{"trials":625,"activeCount":95},[],{"trials":627,"activeCount":95},[],{"trials":629,"activeCount":95},[],{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":169,"soonestReadout":355},[634],{"nctId":352,"briefTitle":353,"status":116,"phases":635,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":636,"interventions":637},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":639,"activeCount":95},[],{"intervention":376,"totalTrials":169,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":656},{"trials":643,"activeCount":95},[],{"trials":645,"activeCount":95},[],{"trials":647,"activeCount":95},[],{"trials":649,"activeCount":95},[],{"trials":651,"activeCount":169,"soonestReadout":355},[652],{"nctId":352,"briefTitle":353,"status":116,"phases":653,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":654,"interventions":655},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":657,"activeCount":95},[],{"intervention":377,"totalTrials":169,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":95},[],{"trials":663,"activeCount":95},[],{"trials":665,"activeCount":95},[],{"trials":667,"activeCount":95},[],{"trials":669,"activeCount":169,"soonestReadout":355},[670],{"nctId":352,"briefTitle":353,"status":116,"phases":671,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":672,"interventions":673},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":675,"activeCount":95},[],{"intervention":378,"totalTrials":169,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":692},{"trials":679,"activeCount":95},[],{"trials":681,"activeCount":95},[],{"trials":683,"activeCount":95},[],{"trials":685,"activeCount":95},[],{"trials":687,"activeCount":169,"soonestReadout":355},[688],{"nctId":352,"briefTitle":353,"status":116,"phases":689,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":690,"interventions":691},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":693,"activeCount":95},[],{"intervention":379,"totalTrials":169,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":710},{"trials":697,"activeCount":95},[],{"trials":699,"activeCount":95},[],{"trials":701,"activeCount":95},[],{"trials":703,"activeCount":95},[],{"trials":705,"activeCount":169,"soonestReadout":355},[706],{"nctId":352,"briefTitle":353,"status":116,"phases":707,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":708,"interventions":709},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":711,"activeCount":95},[],{"intervention":380,"totalTrials":169,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":728},{"trials":715,"activeCount":95},[],{"trials":717,"activeCount":95},[],{"trials":719,"activeCount":95},[],{"trials":721,"activeCount":95},[],{"trials":723,"activeCount":169,"soonestReadout":355},[724],{"nctId":352,"briefTitle":353,"status":116,"phases":725,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":726,"interventions":727},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":729,"activeCount":95},[],{"intervention":381,"totalTrials":169,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":746},{"trials":733,"activeCount":95},[],{"trials":735,"activeCount":95},[],{"trials":737,"activeCount":95},[],{"trials":739,"activeCount":95},[],{"trials":741,"activeCount":169,"soonestReadout":355},[742],{"nctId":352,"briefTitle":353,"status":116,"phases":743,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":744,"interventions":745},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":747,"activeCount":95},[],{"intervention":382,"totalTrials":169,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":764},{"trials":751,"activeCount":95},[],{"trials":753,"activeCount":95},[],{"trials":755,"activeCount":95},[],{"trials":757,"activeCount":95},[],{"trials":759,"activeCount":169,"soonestReadout":355},[760],{"nctId":352,"briefTitle":353,"status":116,"phases":761,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":762,"interventions":763},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":765,"activeCount":95},[],{"intervention":383,"totalTrials":169,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":774,"PHASE4":776,"NA":782},{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":95},[],{"trials":773,"activeCount":95},[],{"trials":775,"activeCount":95},[],{"trials":777,"activeCount":169,"soonestReadout":355},[778],{"nctId":352,"briefTitle":353,"status":116,"phases":779,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":780,"interventions":781},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":783,"activeCount":95},[],{"intervention":384,"totalTrials":169,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":800},{"trials":787,"activeCount":95},[],{"trials":789,"activeCount":95},[],{"trials":791,"activeCount":95},[],{"trials":793,"activeCount":95},[],{"trials":795,"activeCount":169,"soonestReadout":355},[796],{"nctId":352,"briefTitle":353,"status":116,"phases":797,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":798,"interventions":799},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":801,"activeCount":95},[],{"intervention":385,"totalTrials":169,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":812,"NA":818},{"trials":805,"activeCount":95},[],{"trials":807,"activeCount":95},[],{"trials":809,"activeCount":95},[],{"trials":811,"activeCount":95},[],{"trials":813,"activeCount":169,"soonestReadout":355},[814],{"nctId":352,"briefTitle":353,"status":116,"phases":815,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":816,"interventions":817},[87],[359,360],[339,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],{"trials":819,"activeCount":95},[],{"intervention":821,"totalTrials":169,"cells":822},"Bupivacaine Hydrochloride",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":846},{"trials":824,"activeCount":95},[],{"trials":826,"activeCount":95},[],{"trials":828,"activeCount":95},[],{"trials":830,"activeCount":95},[],{"trials":832,"activeCount":169,"soonestReadout":837},[833],{"nctId":834,"briefTitle":835,"status":105,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT07601750","Local Anesthetic Clinical Trial",[87],"2028-12","2025-01-07",400,[297,841],"Anesthesia, Local",[843,821,844,845],"Lidocaine","Mepivacaine Hydrochloride","Chlorprocaine",{"trials":847,"activeCount":95},[],{"intervention":844,"totalTrials":169,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":864},{"trials":851,"activeCount":95},[],{"trials":853,"activeCount":95},[],{"trials":855,"activeCount":95},[],{"trials":857,"activeCount":95},[],{"trials":859,"activeCount":169,"soonestReadout":837},[860],{"nctId":834,"briefTitle":835,"status":105,"phases":861,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":862,"interventions":863},[87],[297,841],[843,821,844,845],{"trials":865,"activeCount":95},[],{"intervention":845,"totalTrials":169,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":882},{"trials":869,"activeCount":95},[],{"trials":871,"activeCount":95},[],{"trials":873,"activeCount":95},[],{"trials":875,"activeCount":95},[],{"trials":877,"activeCount":169,"soonestReadout":837},[878],{"nctId":834,"briefTitle":835,"status":105,"phases":879,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":880,"interventions":881},[87],[297,841],[843,821,844,845],{"trials":883,"activeCount":95},[],{"intervention":165,"totalTrials":169,"cells":885},{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":900},{"trials":887,"activeCount":95},[],{"trials":889,"activeCount":95},[],{"trials":891,"activeCount":95},[],{"trials":893,"activeCount":95},[],{"trials":895,"activeCount":169,"soonestReadout":159},[896],{"nctId":156,"briefTitle":157,"status":105,"phases":897,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":898,"interventions":899},[87],[163],[165,127,166,167,168],{"trials":901,"activeCount":95},[],{"intervention":166,"totalTrials":169,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":918},{"trials":905,"activeCount":95},[],{"trials":907,"activeCount":95},[],{"trials":909,"activeCount":95},[],{"trials":911,"activeCount":95},[],{"trials":913,"activeCount":169,"soonestReadout":159},[914],{"nctId":156,"briefTitle":157,"status":105,"phases":915,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":916,"interventions":917},[87],[163],[165,127,166,167,168],{"trials":919,"activeCount":95},[],{"intervention":167,"totalTrials":169,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":936},{"trials":923,"activeCount":95},[],{"trials":925,"activeCount":95},[],{"trials":927,"activeCount":95},[],{"trials":929,"activeCount":95},[],{"trials":931,"activeCount":169,"soonestReadout":159},[932],{"nctId":156,"briefTitle":157,"status":105,"phases":933,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":934,"interventions":935},[87],[163],[165,127,166,167,168],{"trials":937,"activeCount":95},[],{"intervention":168,"totalTrials":169,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":954},{"trials":941,"activeCount":95},[],{"trials":943,"activeCount":95},[],{"trials":945,"activeCount":95},[],{"trials":947,"activeCount":95},[],{"trials":949,"activeCount":169,"soonestReadout":159},[950],{"nctId":156,"briefTitle":157,"status":105,"phases":951,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":952,"interventions":953},[87],[163],[165,127,166,167,168],{"trials":955,"activeCount":95},[],{"intervention":843,"totalTrials":91,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":972},{"trials":959,"activeCount":95},[],{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[],{"trials":965,"activeCount":95},[],{"trials":967,"activeCount":169,"soonestReadout":837},[968],{"nctId":834,"briefTitle":835,"status":105,"phases":969,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":970,"interventions":971},[87],[297,841],[843,821,844,845],{"trials":973,"activeCount":95},[974],{"nctId":975,"briefTitle":976,"status":142,"phases":977,"primaryCompletion":978,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT01300377","A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery",[88],"2018-12-26","2008-11",300,[982],"Post-operative Pain",[984,843],"Bupivacaine \u002F Lidocaine",{"intervention":39,"totalTrials":169,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":1007,"NA":1009},{"trials":988,"activeCount":95},[],{"trials":990,"activeCount":95},[],{"trials":992,"activeCount":95},[],{"trials":994,"activeCount":169,"soonestReadout":38},[995],{"nctId":36,"briefTitle":37,"status":996,"phases":997,"primaryCompletion":38,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1006},"RECRUITING",[86],"2020-12-31","2018-05-01",20,[1002,1003,1004,1005],"Hemodialysis","Peritoneal Dialysis","Hypercholesterolemia","Atherosclerotic Disease",[39],{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":95},[],{"intervention":59,"totalTrials":1012,"cells":1013},3,{"EARLY_PHASE1":1014,"PHASE1":1028,"PHASE2":1045,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1015,"activeCount":95},[1016],{"nctId":1017,"briefTitle":1018,"status":142,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1000,"conditions":1022,"interventions":1024},"NCT02550327","Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer",[83],"2021-06-14","2016-01",[1023],"Pancreatic Adenocarcinoma",[1025,1026,1027,59],"Nab-paclitaxel","Gemcitabine","Cisplatin",{"trials":1029,"activeCount":95},[1030],{"nctId":1031,"briefTitle":1032,"status":142,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},"NCT02021422","A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy",[84],"2017-12","2021-06","2013-12",13,[1039],"Pancreas Cancer",[1041,1042,1043,1044],"anakinra","Oxaliplatin","Irinotecan","fluorouracil",{"trials":1046,"activeCount":169,"soonestReadout":58},[1047],{"nctId":56,"briefTitle":57,"status":996,"phases":1048,"primaryCompletion":58,"completion":107,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1052},[85],"2021-07-23",24,[1023],[59],{"trials":1054,"activeCount":95},[],{"trials":1056,"activeCount":95},[],{"trials":1058,"activeCount":95},[],{"intervention":1060,"totalTrials":169,"cells":1061},"BDE Injectable Drug",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1063,"activeCount":95},[],{"trials":1065,"activeCount":95},[],{"trials":1067,"activeCount":169,"soonestReadout":1072},[1068],{"nctId":1069,"briefTitle":1070,"status":105,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1078},"NCT07518238","Hernia Abd Wall Recons - BDE vs Exparel",[85],"2029-11-12","2026-01-13",128,[1076,1077],"BDE for Hernia Patients","Exparel for Hernia Patients",[1060,1079],"Exparel Injectable Drug",{"trials":1081,"activeCount":95},[],{"trials":1083,"activeCount":95},[],{"trials":1085,"activeCount":95},[],{"intervention":1079,"totalTrials":169,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1089,"activeCount":95},[],{"trials":1091,"activeCount":95},[],{"trials":1093,"activeCount":169,"soonestReadout":1072},[1094],{"nctId":1069,"briefTitle":1070,"status":105,"phases":1095,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":1096,"interventions":1097},[85],[1076,1077],[1060,1079],{"trials":1099,"activeCount":95},[],{"trials":1101,"activeCount":95},[],{"trials":1103,"activeCount":95},[],{"intervention":44,"totalTrials":169,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1107,"activeCount":95},[],{"trials":1109,"activeCount":95},[],{"trials":1111,"activeCount":169,"soonestReadout":43},[1112],{"nctId":41,"briefTitle":42,"status":185,"phases":1113,"primaryCompletion":43,"completion":58,"start":1114,"enrollment":16,"conditions":1115,"interventions":1118},[84,85],"2021-06-11",[1116,1117],"Metastatic Esophageal Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma",[44,1119],"Ramucirumab",{"trials":1121,"activeCount":95},[],{"trials":1123,"activeCount":95},[],{"trials":1125,"activeCount":95},[],{"intervention":1119,"totalTrials":169,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1129,"activeCount":95},[],{"trials":1131,"activeCount":95},[],{"trials":1133,"activeCount":169,"soonestReadout":43},[1134],{"nctId":41,"briefTitle":42,"status":185,"phases":1135,"primaryCompletion":43,"completion":58,"start":1114,"enrollment":16,"conditions":1136,"interventions":1137},[84,85],[1116,1117],[44,1119],{"trials":1139,"activeCount":95},[],{"trials":1141,"activeCount":95},[],{"trials":1143,"activeCount":95},[],{"intervention":1145,"totalTrials":169,"cells":1146},"Tirzepatide",{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1148,"activeCount":95},[],{"trials":1150,"activeCount":95},[],{"trials":1152,"activeCount":169,"soonestReadout":1157},[1153],{"nctId":1154,"briefTitle":1155,"status":996,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1164},"NCT06517212","Tirzepatide Weight Loss for MRD+ Early Breast Cancer",[85],"2029-08-31","2030-12-31","2024-11-26",48,[24,1162,1163],"Breast Neoplasms","Breast Cancers",[1145],{"trials":1166,"activeCount":95},[],{"trials":1168,"activeCount":95},[],{"trials":1170,"activeCount":95},[],{"intervention":76,"totalTrials":169,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1174,"activeCount":95},[],{"trials":1176,"activeCount":95},[],{"trials":1178,"activeCount":169,"soonestReadout":75},[1179],{"nctId":73,"briefTitle":74,"status":996,"phases":1180,"primaryCompletion":75,"completion":75,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1184},[85],"2018-03-20",15,[21],[76],{"trials":1186,"activeCount":95},[],{"trials":1188,"activeCount":95},[],{"trials":1190,"activeCount":95},[],{"intervention":81,"totalTrials":169,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1194,"activeCount":169,"soonestReadout":80},[1195],{"nctId":78,"briefTitle":79,"status":996,"phases":1196,"primaryCompletion":80,"completion":1197,"start":1198,"enrollment":1000,"conditions":1199,"interventions":1200},[83],"2027-03-31","2020-10-15",[24],[81],{"trials":1202,"activeCount":95},[],{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[],{"trials":1208,"activeCount":95},[],{"trials":1210,"activeCount":95},[],{"intervention":66,"totalTrials":169,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1214,"activeCount":169,"soonestReadout":58},[1215],{"nctId":64,"briefTitle":65,"status":996,"phases":1216,"primaryCompletion":58,"completion":1217,"start":1218,"enrollment":1000,"conditions":1219,"interventions":1221},[83],"2026-12","2024-09-16",[1220,24],"Metastatic Triple-Negative Breast Carcinoma",[66,1222],"Ruxolitinib Oral",{"trials":1224,"activeCount":95},[],{"trials":1226,"activeCount":95},[],{"trials":1228,"activeCount":95},[],{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[],{"intervention":1222,"totalTrials":169,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1241,"PHASE2":1243,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1236,"activeCount":169,"soonestReadout":58},[1237],{"nctId":64,"briefTitle":65,"status":996,"phases":1238,"primaryCompletion":58,"completion":1217,"start":1218,"enrollment":1000,"conditions":1239,"interventions":1240},[83],[1220,24],[66,1222],{"trials":1242,"activeCount":95},[],{"trials":1244,"activeCount":95},[],{"trials":1246,"activeCount":95},[],{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[],{"intervention":71,"totalTrials":169,"cells":1252},{"EARLY_PHASE1":1253,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1254,"activeCount":169,"soonestReadout":70},[1255],{"nctId":68,"briefTitle":69,"status":185,"phases":1256,"primaryCompletion":70,"completion":70,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1261},[83],"2022-07-26",12,[1260],"Esophagogastric Junction Outflow Obstruction",[71],{"trials":1263,"activeCount":95},[],{"trials":1265,"activeCount":95},[],{"trials":1267,"activeCount":95},[],{"trials":1269,"activeCount":95},[],{"trials":1271,"activeCount":95},[],{"intervention":1273,"totalTrials":169,"cells":1274},"Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":95},[],{"trials":1280,"activeCount":95},[],{"trials":1282,"activeCount":95},[],{"trials":1284,"activeCount":95},[],{"trials":1286,"activeCount":169,"soonestReadout":1291},[1287],{"nctId":1288,"briefTitle":1289,"status":116,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1298},"NCT07422012","Tacrolimus in Pregnancy",[],"2028-02","2028-03","2026-05-31",55,[1296,1297],"Unbound Tacrolimus in Pregnant Uterus Transplant Recipients","Whole Blood Tacrolimus in Pregnant Uterus Transplant Recipients",[1273],{"intervention":1300,"totalTrials":169,"cells":1301},"TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg\u002FActuation Powder for Inhalation",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1322},{"trials":1303,"activeCount":95},[],{"trials":1305,"activeCount":95},[],{"trials":1307,"activeCount":95},[],{"trials":1309,"activeCount":95},[],{"trials":1311,"activeCount":95},[1312],{"nctId":1313,"briefTitle":1314,"status":142,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":119,"conditions":1319,"interventions":1321},"NCT05292053","Outcomes of Once-Daily ICS\u002FLABA\u002FLAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations",[87],"2024-09-09","2025-02-09","2022-07-01",[1320],"Copd",[1300],{"trials":1323,"activeCount":95},[],{"intervention":1325,"totalTrials":169,"cells":1326},"Dextenza 0.4Mg Ophthalmic Insert",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1349},{"trials":1328,"activeCount":95},[],{"trials":1330,"activeCount":95},[],{"trials":1332,"activeCount":95},[],{"trials":1334,"activeCount":95},[],{"trials":1336,"activeCount":95},[1337],{"nctId":1338,"briefTitle":1339,"status":1340,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":95,"conditions":1344,"interventions":1347},"NCT04977427","Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","WITHDRAWN",[87],"2021-12-20","2021-08-31",[1345,1346],"Cataract Diabetic","Macula Edema",[1325,1348],"Prednisolone Acetate 1% Oph Susp",{"trials":1350,"activeCount":95},[],{"intervention":1348,"totalTrials":169,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1359,"PHASE4":1361,"NA":1367},{"trials":1354,"activeCount":95},[],{"trials":1356,"activeCount":95},[],{"trials":1358,"activeCount":95},[],{"trials":1360,"activeCount":95},[],{"trials":1362,"activeCount":95},[1363],{"nctId":1338,"briefTitle":1339,"status":1340,"phases":1364,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":95,"conditions":1365,"interventions":1366},[87],[1345,1346],[1325,1348],{"trials":1368,"activeCount":95},[],{"intervention":1370,"totalTrials":169,"cells":1371},"Fasenra, 30 Mg\u002FmL Subcutaneous Solution",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1394},{"trials":1373,"activeCount":95},[],{"trials":1375,"activeCount":95},[],{"trials":1377,"activeCount":95},[],{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[1382],{"nctId":1383,"briefTitle":1384,"status":1340,"phases":1385,"primaryCompletion":1386,"completion":1387,"start":1388,"enrollment":95,"conditions":1389,"interventions":1393},"NCT04108962","Benralizumab in the Treatment of Patients With Severe Asthma With ABPA",[87],"2021-09-24","2021-10-01","2019-12-23",[1390,1391,1392],"ABPA","Severe Asthma","Allergic Bronchopulmonary Aspergillosis",[1370],{"trials":1395,"activeCount":95},[],{"intervention":1397,"totalTrials":169,"cells":1398},"Velaglucerase alfa",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1419},{"trials":1400,"activeCount":95},[],{"trials":1402,"activeCount":95},[],{"trials":1404,"activeCount":95},[],{"trials":1406,"activeCount":95},[],{"trials":1408,"activeCount":95},[1409],{"nctId":1410,"briefTitle":1411,"status":1340,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":95,"conditions":1415,"interventions":1418},"NCT02528617","The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease",[87],"2017-10","2015-07",[1416,1417],"Gaucher Disease Type 1","Gaucher Disease Type 3",[1397],{"trials":1420,"activeCount":95},[],{"intervention":1422,"totalTrials":169,"cells":1423},"Norethindrone acetate",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1450},{"trials":1425,"activeCount":95},[],{"trials":1427,"activeCount":95},[],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[1434],{"nctId":1435,"briefTitle":1436,"status":1437,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1449},"NCT04676061","Effects of a Progestin on Frequent and\u002For Prolonged Bleeding With Nexplanon™","TERMINATED",[87],"2022-07-18","2023-03-10","2021-02-11",51,[1444,1445,1446,1447,1448],"Birth Control","Contraception","Implant","Breakthrough Bleeding","Uterine Bleeding",[1422],{"trials":1451,"activeCount":95},[],{"intervention":1453,"totalTrials":169,"cells":1454},"Nitrous Oxide + Oxygen Gas",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1476},{"trials":1456,"activeCount":95},[],{"trials":1458,"activeCount":95},[],{"trials":1460,"activeCount":95},[],{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[1465],{"nctId":1466,"briefTitle":1467,"status":1437,"phases":1468,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":91,"conditions":1471,"interventions":1474},"NCT03847922","Nitrous Oxide for Analgesia During Office Urethral Bulking",[87],"2020-07-23","2019-02-15",[1472,1473],"Pain","Stress Incontinence, Female",[1453,1475],"lidocaine gel 2%",{"trials":1477,"activeCount":95},[],{"intervention":1475,"totalTrials":169,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1494},{"trials":1481,"activeCount":95},[],{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[],{"trials":1487,"activeCount":95},[],{"trials":1489,"activeCount":95},[1490],{"nctId":1466,"briefTitle":1467,"status":1437,"phases":1491,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":91,"conditions":1492,"interventions":1493},[87],[1472,1473],[1453,1475],{"trials":1495,"activeCount":95},[],{"intervention":152,"totalTrials":169,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1504,"PHASE4":1506,"NA":1512},{"trials":1499,"activeCount":95},[],{"trials":1501,"activeCount":95},[],{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[1508],{"nctId":140,"briefTitle":141,"status":142,"phases":1509,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1510,"interventions":1511},[87],[149,150],[152,127,153,154],{"trials":1513,"activeCount":95},[],{"intervention":153,"totalTrials":169,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1530},{"trials":1517,"activeCount":95},[],{"trials":1519,"activeCount":95},[],{"trials":1521,"activeCount":95},[],{"trials":1523,"activeCount":95},[],{"trials":1525,"activeCount":95},[1526],{"nctId":140,"briefTitle":141,"status":142,"phases":1527,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1528,"interventions":1529},[87],[149,150],[152,127,153,154],{"trials":1531,"activeCount":95},[],{"intervention":154,"totalTrials":169,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1548},{"trials":1535,"activeCount":95},[],{"trials":1537,"activeCount":95},[],{"trials":1539,"activeCount":95},[],{"trials":1541,"activeCount":95},[],{"trials":1543,"activeCount":95},[1544],{"nctId":140,"briefTitle":141,"status":142,"phases":1545,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1546,"interventions":1547},[87],[149,150],[152,127,153,154],{"trials":1549,"activeCount":95},[],{"intervention":1551,"totalTrials":169,"cells":1552},"Anticholinergic",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1577},{"trials":1554,"activeCount":95},[],{"trials":1556,"activeCount":95},[],{"trials":1558,"activeCount":95},[],{"trials":1560,"activeCount":95},[],{"trials":1562,"activeCount":95},[1563],{"nctId":1564,"briefTitle":1565,"status":142,"phases":1566,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":1258,"conditions":1570,"interventions":1575},"NCT03817931","Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder",[87],"2022-02-02","2022-02-26","2019-08-05",[1571,1572,1573,1574],"Overactive Bladder","Dementia","Lower Urinary Tract Symptoms","Incontinence, Urge",[1551,1576],"Beta-3 Agonists, Adrenergic",{"trials":1578,"activeCount":95},[],{"intervention":1576,"totalTrials":169,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1595},{"trials":1582,"activeCount":95},[],{"trials":1584,"activeCount":95},[],{"trials":1586,"activeCount":95},[],{"trials":1588,"activeCount":95},[],{"trials":1590,"activeCount":95},[1591],{"nctId":1564,"briefTitle":1565,"status":142,"phases":1592,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":1258,"conditions":1593,"interventions":1594},[87],[1571,1572,1573,1574],[1551,1576],{"trials":1596,"activeCount":95},[],{"intervention":1598,"totalTrials":169,"cells":1599},"Liposomal bupivacaine",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1624},{"trials":1601,"activeCount":95},[],{"trials":1603,"activeCount":95},[],{"trials":1605,"activeCount":95},[],{"trials":1607,"activeCount":95},[],{"trials":1609,"activeCount":95},[1610],{"nctId":1611,"briefTitle":1612,"status":142,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1622},"NCT04333095","Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery",[87],"2021-06-23","2021-06-26","2020-02-06",70,[1619,1620,1621],"Cardiovascular Surgery","Pain, Postoperative","Block",[1598,1623],"Normal Saline Flush, 0.9% Injectable Solution_#1",{"trials":1625,"activeCount":95},[],{"intervention":1623,"totalTrials":169,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1642},{"trials":1629,"activeCount":95},[],{"trials":1631,"activeCount":95},[],{"trials":1633,"activeCount":95},[],{"trials":1635,"activeCount":95},[],{"trials":1637,"activeCount":95},[1638],{"nctId":1611,"briefTitle":1612,"status":142,"phases":1639,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1640,"interventions":1641},[87],[1619,1620,1621],[1598,1623],{"trials":1643,"activeCount":95},[],{"intervention":1645,"totalTrials":169,"cells":1646},"Nitrofurantoin",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1670},{"trials":1648,"activeCount":95},[],{"trials":1650,"activeCount":95},[],{"trials":1652,"activeCount":95},[],{"trials":1654,"activeCount":95},[],{"trials":1656,"activeCount":95},[1657],{"nctId":1658,"briefTitle":1659,"status":1340,"phases":1660,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":95,"conditions":1663,"interventions":1666},"NCT05274672","Role of Prophylactic Postoperative Antibiotics in HoLEP",[87],"2025-02-20","2023-03-01",[1664,1665],"Benign Prostatic Hyperplasia","Urinary Tract Infections",[1645,1667,1668,1669],"Cephalexin","Sulfamethoxazole Trimethoprim Combination","Ciprofloxacin",{"trials":1671,"activeCount":95},[],{"intervention":1667,"totalTrials":169,"cells":1673},{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1680,"PHASE4":1682,"NA":1688},{"trials":1675,"activeCount":95},[],{"trials":1677,"activeCount":95},[],{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[],{"trials":1683,"activeCount":95},[1684],{"nctId":1658,"briefTitle":1659,"status":1340,"phases":1685,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":95,"conditions":1686,"interventions":1687},[87],[1664,1665],[1645,1667,1668,1669],{"trials":1689,"activeCount":95},[],{"intervention":1668,"totalTrials":169,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1706},{"trials":1693,"activeCount":95},[],{"trials":1695,"activeCount":95},[],{"trials":1697,"activeCount":95},[],{"trials":1699,"activeCount":95},[],{"trials":1701,"activeCount":95},[1702],{"nctId":1658,"briefTitle":1659,"status":1340,"phases":1703,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":95,"conditions":1704,"interventions":1705},[87],[1664,1665],[1645,1667,1668,1669],{"trials":1707,"activeCount":95},[],{"intervention":1669,"totalTrials":169,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1724},{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[],{"trials":1717,"activeCount":95},[],{"trials":1719,"activeCount":95},[1720],{"nctId":1658,"briefTitle":1659,"status":1340,"phases":1721,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":95,"conditions":1722,"interventions":1723},[87],[1664,1665],[1645,1667,1668,1669],{"trials":1725,"activeCount":95},[],{"intervention":1727,"totalTrials":169,"cells":1728},"BYDUREON",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1748,"NA":1750},{"trials":1730,"activeCount":95},[],{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[],{"trials":1736,"activeCount":95},[1737],{"nctId":1738,"briefTitle":1739,"status":142,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1747},"NCT02251431","Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome",[86],"2019-12","2015-11",57,[1745,359,1746],"Type 2 Diabetes Mellitus","Left Ventricular Diastolic Dysfunction",[1727],{"trials":1749,"activeCount":95},[],{"trials":1751,"activeCount":95},[],{"intervention":1753,"totalTrials":169,"cells":1754},"Bilateral abdominal Lap-TAP",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1761,"PHASE4":1772,"NA":1774},{"trials":1756,"activeCount":95},[],{"trials":1758,"activeCount":95},[],{"trials":1760,"activeCount":95},[],{"trials":1762,"activeCount":95},[1763],{"nctId":1764,"briefTitle":1765,"status":1340,"phases":1766,"primaryCompletion":1767,"completion":1767,"start":1768,"enrollment":95,"conditions":1769,"interventions":1771},"NCT04655339","Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids",[85,86],"2021-09-03","2020-01-24",[1770],"Opioid Use",[1753],{"trials":1773,"activeCount":95},[],{"trials":1775,"activeCount":95},[],{"intervention":1777,"totalTrials":169,"cells":1778},"Cholates",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1780,"activeCount":95},[],{"trials":1782,"activeCount":95},[],{"trials":1784,"activeCount":95},[1785],{"nctId":1786,"briefTitle":1787,"status":1437,"phases":1788,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":1792,"conditions":1793,"interventions":1794},"NCT01907074","Quantitative Liver Function Tests Using Cholates",[85],"2020-05-19","2025-05-20","2011-06-23",103,[149],[1777],{"trials":1796,"activeCount":95},[],{"trials":1798,"activeCount":95},[],{"trials":1800,"activeCount":95},[],{"intervention":1802,"totalTrials":169,"cells":1803},"DC Vaccine & Cyclophosphamide",{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1805,"activeCount":95},[],{"trials":1807,"activeCount":95},[],{"trials":1809,"activeCount":95},[1810],{"nctId":1811,"briefTitle":1812,"status":1437,"phases":1813,"primaryCompletion":1814,"completion":1815,"start":1816,"enrollment":1817,"conditions":1818,"interventions":1820},"NCT00722098","Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients",[85],"2011-04","2012-07","2008-06",9,[1819],"Malignant Melanoma Stage IV",[1802,1821],"DC Vaccine & Placebo",{"trials":1823,"activeCount":95},[],{"trials":1825,"activeCount":95},[],{"trials":1827,"activeCount":95},[],{"intervention":1821,"totalTrials":169,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1831,"activeCount":95},[],{"trials":1833,"activeCount":95},[],{"trials":1835,"activeCount":95},[1836],{"nctId":1811,"briefTitle":1812,"status":1437,"phases":1837,"primaryCompletion":1814,"completion":1815,"start":1816,"enrollment":1817,"conditions":1838,"interventions":1839},[85],[1819],[1802,1821],{"trials":1841,"activeCount":95},[],{"trials":1843,"activeCount":95},[],{"trials":1845,"activeCount":95},[],{"intervention":1847,"totalTrials":169,"cells":1848},"Drug 1: LY3023414; Drug 2: Prexasertib",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1866,"PHASE4":1868,"NA":1870},{"trials":1850,"activeCount":95},[],{"trials":1852,"activeCount":95},[],{"trials":1854,"activeCount":95},[1855],{"nctId":1856,"briefTitle":1857,"status":142,"phases":1858,"primaryCompletion":1859,"completion":1860,"start":1861,"enrollment":1862,"conditions":1863,"interventions":1865},"NCT04032080","LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer",[85],"2022-06-01","2022-11-26","2019-09-05",10,[1864],"Triple Negative Breast Cancer",[1847],{"trials":1867,"activeCount":95},[],{"trials":1869,"activeCount":95},[],{"trials":1871,"activeCount":95},[],{"intervention":1873,"totalTrials":169,"cells":1874},"Dexmedetomidine",{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1876,"activeCount":95},[],{"trials":1878,"activeCount":95},[],{"trials":1880,"activeCount":95},[1881],{"nctId":1882,"briefTitle":1883,"status":142,"phases":1884,"primaryCompletion":1885,"completion":1885,"start":1886,"enrollment":1887,"conditions":1888,"interventions":1890},"NCT00345384","Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients",[84,85],"2010-01","2008-05",38,[982,1889],"Respiratory Depression",[1873],{"trials":1892,"activeCount":95},[],{"trials":1894,"activeCount":95},[],{"trials":1896,"activeCount":95},[],{"intervention":1898,"totalTrials":169,"cells":1899},"Hydroxychloroquine",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1901,"activeCount":95},[],{"trials":1903,"activeCount":95},[],{"trials":1905,"activeCount":95},[1906],{"nctId":1907,"briefTitle":1908,"status":142,"phases":1909,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":1912,"conditions":1913,"interventions":1915},"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",[85],"2020-06-30","2020-04-03",221,[1914],"COVID-19",[1898],{"trials":1917,"activeCount":95},[],{"trials":1919,"activeCount":95},[],{"trials":1921,"activeCount":95},[],{"intervention":1923,"totalTrials":169,"cells":1924},"IL15-DC Vaccine",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1926,"activeCount":95},[],{"trials":1928,"activeCount":95},[],{"trials":1930,"activeCount":95},[1931],{"nctId":1932,"briefTitle":1933,"status":142,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1000,"conditions":1937,"interventions":1939},"NCT01189383","IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",[84,85],"2016-12","2011-01",[1938,1819],"Malignant Melanoma Stage III",[1923],{"trials":1941,"activeCount":95},[],{"trials":1943,"activeCount":95},[],{"trials":1945,"activeCount":95},[],{"intervention":1947,"totalTrials":169,"cells":1948},"Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1950,"activeCount":95},[],{"trials":1952,"activeCount":95},[],{"trials":1954,"activeCount":95},[1955],{"nctId":1956,"briefTitle":1957,"status":1340,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":95,"conditions":1961,"interventions":1963},"NCT00637117","Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.",[84,85],"2010-03","2008-07",[1962],"Lymphoma",[1947],{"trials":1965,"activeCount":95},[],{"trials":1967,"activeCount":95},[],{"trials":1969,"activeCount":95},[],{"intervention":1971,"totalTrials":169,"cells":1972},"Bortezomib",{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1974,"activeCount":95},[],{"trials":1976,"activeCount":95},[],{"trials":1978,"activeCount":95},[1979],{"nctId":1980,"briefTitle":1981,"status":1982,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1990},"NCT01158105","Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)","UNKNOWN",[85],"2013-05","2017-01","2010-06",25,[1989],"Chronic Graft-versus-host Disease",[1971],{"trials":1992,"activeCount":95},[],{"trials":1994,"activeCount":95},[],{"trials":1996,"activeCount":95},[],{"intervention":1998,"totalTrials":169,"cells":1999},"apremilast",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2001,"activeCount":95},[],{"trials":2003,"activeCount":95},[],{"trials":2005,"activeCount":95},[2006],{"nctId":2007,"briefTitle":2008,"status":142,"phases":2009,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2015},"NCT01250548","The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)",[85],"2014-06","2010-05",34,[2014],"Rheumatoid Arthritis",[1998],{"trials":2017,"activeCount":95},[],{"trials":2019,"activeCount":95},[],{"trials":2021,"activeCount":95},[],{"intervention":2023,"totalTrials":169,"cells":2024},"Clofarabine and Cytarabine",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2026,"activeCount":95},[],{"trials":2028,"activeCount":95},[],{"trials":2030,"activeCount":95},[2031],{"nctId":2032,"briefTitle":2033,"status":142,"phases":2034,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2043},"NCT00334074","Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS",[85],"2007-02","2008-02","2005-08",30,[2040,2041,2042],"Acute Myelogenous Leukemia","Myelodysplastic Syndromes","Chronic Myelogenous Leukemia",[2023],{"trials":2045,"activeCount":95},[],{"trials":2047,"activeCount":95},[],{"trials":2049,"activeCount":95},[],{"intervention":2051,"totalTrials":169,"cells":2052},"Inhaled Nitric Oxide",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2054,"activeCount":95},[],{"trials":2056,"activeCount":95},[],{"trials":2058,"activeCount":95},[2059],{"nctId":2060,"briefTitle":2061,"status":142,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":2065,"conditions":2066,"interventions":2068},"NCT01172691","Trial of Inhaled Nitric Oxide (iNO) on Ischemia \u002F Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts",[85],"2014-01-22","2010-07",23,[2067],"Liver Transplant",[2051],{"trials":2070,"activeCount":95},[],{"trials":2072,"activeCount":95},[],{"trials":2074,"activeCount":95},[],{"intervention":2076,"totalTrials":169,"cells":2077},"Clofarabine with Busulfan",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2079,"activeCount":95},[],{"trials":2081,"activeCount":95},[],{"trials":2083,"activeCount":95},[2084],{"nctId":2085,"briefTitle":2086,"status":142,"phases":2087,"primaryCompletion":2088,"completion":2089,"start":2090,"enrollment":1000,"conditions":2091,"interventions":2094},"NCT00852163","Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen",[85],"2011-08","2011-12","2007-03",[2092,2093],"Leukemia","Myelodysplastic Syndrome",[2076],{"trials":2096,"activeCount":95},[],{"trials":2098,"activeCount":95},[],{"trials":2100,"activeCount":95},[],{"intervention":2102,"totalTrials":169,"cells":2103},"Envarsus",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2105,"activeCount":95},[],{"trials":2107,"activeCount":95},[],{"trials":2109,"activeCount":95},[2110],{"nctId":2111,"briefTitle":2112,"status":142,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":214,"conditions":2116,"interventions":2120},"NCT03373227","Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen",[85],"2023-12-30","2017-12-04",[2117,2118,2119],"Heart Transplant Rejection","Graft Failure","Compliance, Patient",[2102],{"trials":2122,"activeCount":95},[],{"trials":2124,"activeCount":95},[],{"trials":2126,"activeCount":95},[],{"intervention":2128,"totalTrials":169,"cells":2129},"LA TNBC: DC vaccine+Preop chemo",{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2134,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2131,"activeCount":95},[],{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[2136],{"nctId":2137,"briefTitle":2138,"status":142,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":1862,"conditions":2142,"interventions":2143},"NCT02018458","Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer",[84,85],"2019-09-18","2014-05",[24],[2128,2144],"ER+\u002FHER2-BC:DC vaccine+Preop chemo",{"trials":2146,"activeCount":95},[],{"trials":2148,"activeCount":95},[],{"trials":2150,"activeCount":95},[],{"intervention":2144,"totalTrials":169,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2154,"activeCount":95},[],{"trials":2156,"activeCount":95},[],{"trials":2158,"activeCount":95},[2159],{"nctId":2137,"briefTitle":2138,"status":142,"phases":2160,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":1862,"conditions":2161,"interventions":2162},[84,85],[24],[2128,2144],{"trials":2164,"activeCount":95},[],{"trials":2166,"activeCount":95},[],{"trials":2168,"activeCount":95},[],{"intervention":2170,"totalTrials":169,"cells":2171},"DC Vaccine and Cyclophosphamide",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2173,"activeCount":95},[],{"trials":2175,"activeCount":95},[],{"trials":2177,"activeCount":95},[2178],{"nctId":2179,"briefTitle":2180,"status":142,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2187},"NCT00313235","Combined Modality Treatment for Patients With Stage IV Melanoma",[84,85],"2011-06","2012-06","2006-03",41,[1819],[2170],{"trials":2189,"activeCount":95},[],{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[],{"intervention":2195,"totalTrials":169,"cells":2196},"All patients- TAS-102",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2198,"activeCount":95},[],{"trials":2200,"activeCount":95},[],{"trials":2202,"activeCount":95},[2203],{"nctId":2204,"briefTitle":2205,"status":1437,"phases":2206,"primaryCompletion":2207,"completion":2208,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2213},"NCT04042714","TAS-102 in Extrapulmonary Neuroendocrine Carcinoma",[85],"2025-09-15","2025-10-15","2019-08-15",14,[2212],"High-grade Extra Pulmonary Neuroendocrine Cancer",[2195],{"trials":2215,"activeCount":95},[],{"trials":2217,"activeCount":95},[],{"trials":2219,"activeCount":95},[],{"intervention":2221,"totalTrials":169,"cells":2222},"Replagal",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2224,"activeCount":95},[],{"trials":2226,"activeCount":95},[],{"trials":2228,"activeCount":95},[2229],{"nctId":2230,"briefTitle":2231,"status":142,"phases":2232,"primaryCompletion":1036,"completion":1036,"start":2233,"enrollment":1037,"conditions":2234,"interventions":2236},"NCT00068107","Dosing Study of Replagal in Patients With Fabry Disease",[85],"2003-09",[2235],"Fabry Disease",[2221],{"trials":2238,"activeCount":95},[],{"trials":2240,"activeCount":95},[],{"trials":2242,"activeCount":95},[],{"intervention":2244,"totalTrials":169,"cells":2245},"Dendritic cell vaccination",{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2247,"activeCount":95},[],{"trials":2249,"activeCount":95},[],{"trials":2251,"activeCount":95},[2252],{"nctId":2253,"briefTitle":2254,"status":142,"phases":2255,"primaryCompletion":2256,"completion":2256,"start":2257,"enrollment":2038,"conditions":2258,"interventions":2261},"NCT00125749","Vaccination of Patients With Stage IV Melanoma With Dendritic Cells",[84,85],"2007-06","2005-07",[2259,2260],"Melanoma","Neoplasm Metastasis",[2244],{"trials":2263,"activeCount":95},[],{"trials":2265,"activeCount":95},[],{"trials":2267,"activeCount":95},[],{"intervention":2269,"totalTrials":169,"cells":2270},"Triheptanoin",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2272,"activeCount":95},[],{"trials":2274,"activeCount":95},[],{"trials":2276,"activeCount":95},[2277],{"nctId":2278,"briefTitle":2279,"status":142,"phases":2280,"primaryCompletion":1414,"completion":1414,"start":2281,"enrollment":2065,"conditions":2282,"interventions":2286},"NCT00947960","Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease",[85],"2009-06",[2283,2284,2285],"Adult Polyglucosan Body Disease","Glycogen Brancher Enzyme Deficiency","Glycogen Storage Disease Type IV",[2269],{"trials":2288,"activeCount":95},[],{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"intervention":2294,"totalTrials":1012,"cells":2295},"Islet cell transplantation",{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2297,"activeCount":95},[],{"trials":2299,"activeCount":95},[2300,2309,2317],{"nctId":2301,"briefTitle":2302,"status":142,"phases":2303,"primaryCompletion":2304,"completion":2304,"start":1960,"enrollment":169,"conditions":2305,"interventions":2308},"NCT00530686","Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment",[84],"2017-04",[2306,2307],"Islet Cell Transplantation","Type 1 Diabetes",[2294],{"nctId":2310,"briefTitle":2311,"status":142,"phases":2312,"primaryCompletion":2313,"completion":2313,"start":2314,"enrollment":9,"conditions":2315,"interventions":2316},"NCT00214786","Pancreatic Islet Cell Transplantation",[84],"2007-07","2005-04",[2307],[2294],{"nctId":2318,"briefTitle":2319,"status":1340,"phases":2320,"primaryCompletion":1985,"completion":1985,"start":1960,"enrollment":95,"conditions":2321,"interventions":2322},"NCT03047200","Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression",[84],[2306,2307],[2294],{"trials":2324,"activeCount":95},[],{"trials":2326,"activeCount":95},[],{"trials":2328,"activeCount":95},[],{"trials":2330,"activeCount":95},[],{"intervention":2332,"totalTrials":169,"cells":2333},"Anakinra plus Standard of Care",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2335,"activeCount":95},[],{"trials":2337,"activeCount":95},[2338],{"nctId":2339,"briefTitle":2340,"status":142,"phases":2341,"primaryCompletion":2342,"completion":2342,"start":2343,"enrollment":1862,"conditions":2344,"interventions":2346},"NCT01802970","Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients",[84],"2017-01-04","2012-12",[2345],"Metastatic Breast Cancer",[2332],{"trials":2348,"activeCount":95},[],{"trials":2350,"activeCount":95},[],{"trials":2352,"activeCount":95},[],{"trials":2354,"activeCount":95},[],{"intervention":1042,"totalTrials":169,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2358,"activeCount":95},[],{"trials":2360,"activeCount":95},[2361],{"nctId":1031,"briefTitle":1032,"status":142,"phases":2362,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":2363,"interventions":2364},[84],[1039],[1041,1042,1043,1044],{"trials":2366,"activeCount":95},[],{"trials":2368,"activeCount":95},[],{"trials":2370,"activeCount":95},[],{"trials":2372,"activeCount":95},[],{"intervention":1043,"totalTrials":169,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2376,"activeCount":95},[],{"trials":2378,"activeCount":95},[2379],{"nctId":1031,"briefTitle":1032,"status":142,"phases":2380,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":2381,"interventions":2382},[84],[1039],[1041,1042,1043,1044],{"trials":2384,"activeCount":95},[],{"trials":2386,"activeCount":95},[],{"trials":2388,"activeCount":95},[],{"trials":2390,"activeCount":95},[],{"intervention":1044,"totalTrials":169,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2394,"activeCount":95},[],{"trials":2396,"activeCount":95},[2397],{"nctId":1031,"briefTitle":1032,"status":142,"phases":2398,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":2399,"interventions":2400},[84],[1039],[1041,1042,1043,1044],{"trials":2402,"activeCount":95},[],{"trials":2404,"activeCount":95},[],{"trials":2406,"activeCount":95},[],{"trials":2408,"activeCount":95},[],{"intervention":2410,"totalTrials":169,"cells":2411},"DC Vaccine + Standard of Care Chemotherapy",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2425,"PHASE3":2427,"PHASE4":2429,"NA":2431},{"trials":2413,"activeCount":95},[],{"trials":2415,"activeCount":95},[2416],{"nctId":2417,"briefTitle":2418,"status":1437,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":19,"conditions":2422,"interventions":2424},"NCT02548169","Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer",[84],"2017-04-24","2015-08",[2423],"Pancreatic Cancer",[2410],{"trials":2426,"activeCount":95},[],{"trials":2428,"activeCount":95},[],{"trials":2430,"activeCount":95},[],{"trials":2432,"activeCount":95},[],{"intervention":2434,"totalTrials":169,"cells":2435},"high-titer anti-Sars-CoV-2 plasma",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2437,"activeCount":95},[],{"trials":2439,"activeCount":95},[2440],{"nctId":2441,"briefTitle":2442,"status":1340,"phases":2443,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":95,"conditions":2446,"interventions":2448},"NCT04333251","Study Testing Convalescent Plasma vs Best Supportive Care",[84],"2021-09-07","2020-04-17",[2447],"Pneumonia, Interstitial",[2434],{"trials":2450,"activeCount":95},[],{"trials":2452,"activeCount":95},[],{"trials":2454,"activeCount":95},[],{"trials":2456,"activeCount":95},[],{"intervention":2458,"totalTrials":169,"cells":2459},"Dendritic Cell Vaccine",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2473,"PHASE3":2475,"PHASE4":2477,"NA":2479},{"trials":2461,"activeCount":95},[],{"trials":2463,"activeCount":95},[2464],{"nctId":2465,"briefTitle":2466,"status":142,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":979,"enrollment":2469,"conditions":2470,"interventions":2472},"NCT00796770","Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)",[84],"2011-09",19,[2471],"HIV",[2458],{"trials":2474,"activeCount":95},[],{"trials":2476,"activeCount":95},[],{"trials":2478,"activeCount":95},[],{"trials":2480,"activeCount":95},[],{"intervention":2482,"totalTrials":169,"cells":2483},"Heplisav-B",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2485,"activeCount":95},[],{"trials":2487,"activeCount":95},[2488],{"nctId":2489,"briefTitle":2490,"status":142,"phases":2491,"primaryCompletion":2492,"completion":2492,"start":2493,"enrollment":1862,"conditions":2494,"interventions":2496},"NCT04199715","Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients",[84],"2022-01-20","2019-12-03",[2495],"Hepatitis B",[2482],{"trials":2498,"activeCount":95},[],{"trials":2500,"activeCount":95},[],{"trials":2502,"activeCount":95},[],{"trials":2504,"activeCount":95},[],{"intervention":2506,"totalTrials":91,"cells":2507},"Curcumin",{"EARLY_PHASE1":2508,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2509,"activeCount":95},[2510,2519],{"nctId":2511,"briefTitle":2512,"status":1340,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":95,"conditions":2516,"interventions":2518},"NCT02554344","Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)",[83],"2017-07-11","2015-06-22",[2517],"Cervical Intraepithelial Neoplasia",[2506],{"nctId":2520,"briefTitle":2521,"status":1437,"phases":2522,"primaryCompletion":2523,"completion":2523,"start":2524,"enrollment":1182,"conditions":2525,"interventions":2527},"NCT02724202","Curcumin in Combination With 5FU for Colon Cancer",[83],"2020-01-10","2018-02-20",[2526],"Metastatic Colon Cancer",[2506,2528],"5-flurorouracil",{"trials":2530,"activeCount":95},[],{"trials":2532,"activeCount":95},[],{"trials":2534,"activeCount":95},[],{"trials":2536,"activeCount":95},[],{"trials":2538,"activeCount":95},[],{"intervention":1025,"totalTrials":169,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2542,"activeCount":95},[2543],{"nctId":1017,"briefTitle":1018,"status":142,"phases":2544,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1000,"conditions":2545,"interventions":2546},[83],[1023],[1025,1026,1027,59],{"trials":2548,"activeCount":95},[],{"trials":2550,"activeCount":95},[],{"trials":2552,"activeCount":95},[],{"trials":2554,"activeCount":95},[],{"trials":2556,"activeCount":95},[],{"intervention":1026,"totalTrials":169,"cells":2558},{"EARLY_PHASE1":2559,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2560,"activeCount":95},[2561],{"nctId":1017,"briefTitle":1018,"status":142,"phases":2562,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1000,"conditions":2563,"interventions":2564},[83],[1023],[1025,1026,1027,59],{"trials":2566,"activeCount":95},[],{"trials":2568,"activeCount":95},[],{"trials":2570,"activeCount":95},[],{"trials":2572,"activeCount":95},[],{"trials":2574,"activeCount":95},[],{"intervention":1027,"totalTrials":169,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2583,"PHASE2":2585,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2578,"activeCount":95},[2579],{"nctId":1017,"briefTitle":1018,"status":142,"phases":2580,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1000,"conditions":2581,"interventions":2582},[83],[1023],[1025,1026,1027,59],{"trials":2584,"activeCount":95},[],{"trials":2586,"activeCount":95},[],{"trials":2588,"activeCount":95},[],{"trials":2590,"activeCount":95},[],{"trials":2592,"activeCount":95},[],{"intervention":2528,"totalTrials":169,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2601,"PHASE2":2603,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2596,"activeCount":95},[2597],{"nctId":2520,"briefTitle":2521,"status":1437,"phases":2598,"primaryCompletion":2523,"completion":2523,"start":2524,"enrollment":1182,"conditions":2599,"interventions":2600},[83],[2526],[2506,2528],{"trials":2602,"activeCount":95},[],{"trials":2604,"activeCount":95},[],{"trials":2606,"activeCount":95},[],{"trials":2608,"activeCount":95},[],{"trials":2610,"activeCount":95},[],{"intervention":2612,"totalTrials":169,"cells":2613},"Pitocin",{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2615,"activeCount":95},[],{"trials":2617,"activeCount":95},[],{"trials":2619,"activeCount":95},[],{"trials":2621,"activeCount":95},[],{"trials":2623,"activeCount":95},[],{"trials":2625,"activeCount":95},[2626],{"nctId":2627,"briefTitle":2628,"status":1437,"phases":2629,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":16,"conditions":2633,"interventions":2637},"NCT02910115","Cooling the Uterus in C-section After Dysfunctional Labor",[88],"2017-11-10","2018-11-10","2015-05-14",[2634,2635,2636],"Blood Loss","Dysfunctional Labor","Uterine Atony",[2612],{"intervention":984,"totalTrials":169,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2641,"activeCount":95},[],{"trials":2643,"activeCount":95},[],{"trials":2645,"activeCount":95},[],{"trials":2647,"activeCount":95},[],{"trials":2649,"activeCount":95},[],{"trials":2651,"activeCount":95},[2652],{"nctId":975,"briefTitle":976,"status":142,"phases":2653,"primaryCompletion":978,"completion":978,"start":979,"enrollment":980,"conditions":2654,"interventions":2655},[88],[982],[984,843],{"intervention":2657,"totalTrials":169,"cells":2658},"Angiotensin-Converting Enzyme Inhibitors",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2660,"activeCount":95},[],{"trials":2662,"activeCount":95},[],{"trials":2664,"activeCount":95},[],{"trials":2666,"activeCount":95},[],{"trials":2668,"activeCount":95},[],{"trials":2670,"activeCount":95},[2671],{"nctId":2672,"briefTitle":2673,"status":142,"phases":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":2678,"interventions":2681},"NCT00224809","Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation",[88],"2007-05","2002-09",250,[31,2679,2680],"Heart Diseases","Coronary Disease",[2657,2682,2683,2684,2685],"Angiotensin Receptor Blockers","Spironolactone","Aspirin","Clopidogrel",{"intervention":2682,"totalTrials":169,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2692,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2689,"activeCount":95},[],{"trials":2691,"activeCount":95},[],{"trials":2693,"activeCount":95},[],{"trials":2695,"activeCount":95},[],{"trials":2697,"activeCount":95},[],{"trials":2699,"activeCount":95},[2700],{"nctId":2672,"briefTitle":2673,"status":142,"phases":2701,"completion":2675,"start":2676,"enrollment":2677,"conditions":2702,"interventions":2703},[88],[31,2679,2680],[2657,2682,2683,2684,2685],{"intervention":2683,"totalTrials":169,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2707,"activeCount":95},[],{"trials":2709,"activeCount":95},[],{"trials":2711,"activeCount":95},[],{"trials":2713,"activeCount":95},[],{"trials":2715,"activeCount":95},[],{"trials":2717,"activeCount":95},[2718],{"nctId":2672,"briefTitle":2673,"status":142,"phases":2719,"completion":2675,"start":2676,"enrollment":2677,"conditions":2720,"interventions":2721},[88],[31,2679,2680],[2657,2682,2683,2684,2685],{"intervention":2684,"totalTrials":169,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2725,"activeCount":95},[],{"trials":2727,"activeCount":95},[],{"trials":2729,"activeCount":95},[],{"trials":2731,"activeCount":95},[],{"trials":2733,"activeCount":95},[],{"trials":2735,"activeCount":95},[2736],{"nctId":2672,"briefTitle":2673,"status":142,"phases":2737,"completion":2675,"start":2676,"enrollment":2677,"conditions":2738,"interventions":2739},[88],[31,2679,2680],[2657,2682,2683,2684,2685],{"intervention":2685,"totalTrials":169,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2750,"NA":2752},{"trials":2743,"activeCount":95},[],{"trials":2745,"activeCount":95},[],{"trials":2747,"activeCount":95},[],{"trials":2749,"activeCount":95},[],{"trials":2751,"activeCount":95},[],{"trials":2753,"activeCount":95},[2754],{"nctId":2672,"briefTitle":2673,"status":142,"phases":2755,"completion":2675,"start":2676,"enrollment":2677,"conditions":2756,"interventions":2757},[88],[31,2679,2680],[2657,2682,2683,2684,2685],{"intervention":2759,"totalTrials":169,"cells":2760},"Genetic Testing",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":95},[],{"trials":2764,"activeCount":95},[],{"trials":2766,"activeCount":95},[],{"trials":2768,"activeCount":95},[],{"trials":2770,"activeCount":95},[],{"trials":2772,"activeCount":95},[2773],{"nctId":2774,"briefTitle":2775,"status":142,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2782},"NCT03645993","Early Onset Alzheimer's Disease Genomic Study",[],"2024-04-24","2017-06-16",26,[2781],"Alzheimer Disease",[2759],{"intervention":2784,"totalTrials":169,"cells":2785},"N-acetylcysteine",{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2787,"activeCount":95},[],{"trials":2789,"activeCount":95},[],{"trials":2791,"activeCount":95},[],{"trials":2793,"activeCount":95},[],{"trials":2795,"activeCount":95},[],{"trials":2797,"activeCount":95},[2798],{"nctId":2799,"briefTitle":2800,"status":142,"phases":2801,"primaryCompletion":2802,"completion":2802,"start":2313,"enrollment":2038,"conditions":2803,"interventions":2805},"NCT01907061","Acute Renal Failure Post Liver Transplantation",[88],"2014-07",[2804],"Acute Renal Failure",[2784],{"intervention":2807,"totalTrials":169,"cells":2808},"FOLFIRINOX Regimen",{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2810,"activeCount":95},[],{"trials":2812,"activeCount":95},[],{"trials":2814,"activeCount":95},[],{"trials":2816,"activeCount":95},[],{"trials":2818,"activeCount":95},[],{"trials":2820,"activeCount":95},[2821],{"nctId":2822,"briefTitle":2823,"status":1982,"phases":2824,"primaryCompletion":2825,"completion":2826,"start":2827,"enrollment":2038,"conditions":2828,"interventions":2831},"NCT01771146","Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer",[88],"2017-09","2020-09","2012-10",[1039,2829,2830],"Localized Pancreas Cancer","Non-metastatic Pancreas Cancer",[2807]]